Online inquiry

IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8977MR)

This product GTTS-WQ8977MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL22 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_020525.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50616
UniProt ID Q9GZX6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8977MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13340MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ7109MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ4510MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ1924MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ14536MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ8895MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ9307MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ10079MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19TNF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW